


1
more

**TRANSMITTAL
FORM**



Application Serial Number	09/708,506
Filing Date	November 9, 2000
First Named Inventor	Hartmann
Group Art Unit	1647
Examiner Name	DeBerry, Regina M.
Attorney Docket No.	MERCK-2056
Patent No.	Not applicable
Issue Date	Not applicable


ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form <input type="checkbox"/> Amendment/Response <input type="checkbox"/> Preliminary <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____] <input type="checkbox"/> Petition for Extension of Time <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement <input checked="" type="checkbox"/> Form PTO-1449 <input checked="" type="checkbox"/> Copies of IDS Citations (A82-A96 and C191-C244) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Sequence Listing submission <input type="checkbox"/> Paper Copy/CD <input type="checkbox"/> Computer Readable Copy <input type="checkbox"/> Statement verifying identity of above	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application <input type="checkbox"/> Formal Drawing(s) <input type="checkbox"/> Request For Continued Examination (RCE) Transmittal <input type="checkbox"/> Power of Attorney (Revocation of Prior Powers) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> CD(s) for large table or computer program <input type="checkbox"/> Amendment After Allowance <input type="checkbox"/> Request for Certificate of Correction <input type="checkbox"/> Certificate of Correction (in duplicate)	<input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences <input type="checkbox"/> Appeal Brief (in triplicate) <input type="checkbox"/> Status Inquiry <input checked="" type="checkbox"/> Return Receipt Postcard <input checked="" type="checkbox"/> Certificate of First Class Mail <input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8 <input type="checkbox"/> Additional Enclosure(s) (please identify below)
---	---	--

CORRESPONDENCE ADDRESS


Direct all correspondence to: Patent Administrator
 Testa, Hurwitz & Thibault, LLP
 High Street Tower
 125 High Street
 Boston, MA 02110
 Tel. No.: (617) 248-7000
 Fax No.: (617) 248-7100

SIGNATURE BLOCK


Respectfully submitted,

 Brian Fairchild, Ph.D.
 Attorney for Applicants
 Testa, Hurwitz & Thibault, LLP
 High Street Tower
 125 High Street
 Boston, MA 02110

Date: March 9, 2004
 Reg. No. 48,645
 Tel. No.: (617) 248-7697
 Fax No.: (617) 248-7100

1647
\$
2

FEE TRANSMITTAL FY 2004 	Complete if Known		
	Application Serial Number	09/708,506	
	Filing Date	November 9, 2000	
	First Named Inventor	Hartmann	
	Group Art Unit	1647	
	Examiner Name	DeBerry, Regina M.	
		Attorney Docket No.	MERCK-2056

METHOD OF PAYMENT	FEE CALCULATION (continued)																																																																																																
1. <input checked="" type="checkbox"/> Payment Enclosed: <input checked="" type="checkbox"/> Check <input type="checkbox"/> Money Order <input type="checkbox"/> Other 2. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to credit or charge any fee indicated below for this submission to Deposit Account No. 20-0531. <input type="checkbox"/> Required Fees (copy of this sheet enclosed). <input checked="" type="checkbox"/> Additional fee required under 37 CFR 1.16 and 1.17. <input checked="" type="checkbox"/> Overpayment Credit. 3. <input type="checkbox"/> Applicant claims small entity status.	3. ADDITIONAL FEES <table border="1" style="width: 100%; border-collapse: collapse; font-size: x-small;"> <thead> <tr> <th>Large Entity Fee (\$)</th> <th>Small Entity Fee (\$)</th> <th>Fee Description</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr><td>130</td><td>65</td><td>Surcharge - late filing fee or oath</td><td></td></tr> <tr><td>50</td><td>25</td><td>Surcharge - late provisional filing fee or cover sheet</td><td></td></tr> <tr><td>130</td><td>130</td><td>Non-English specification</td><td></td></tr> <tr><td>2,520</td><td>2,520</td><td>Request for ex parte reexamination</td><td></td></tr> <tr><td>110</td><td>55</td><td>Extension for reply within first month</td><td></td></tr> <tr><td>420</td><td>210</td><td>Extension for reply within second month</td><td></td></tr> <tr><td>950</td><td>475</td><td>Extension for reply within third month</td><td></td></tr> <tr><td>1480</td><td>740</td><td>Extension for reply within fourth month</td><td></td></tr> <tr><td>2010</td><td>1005</td><td>Extension for reply within fifth month</td><td></td></tr> <tr><td>330</td><td>165</td><td>Notice of Appeal</td><td></td></tr> <tr><td>330</td><td>165</td><td>Filing a brief in support of an appeal</td><td></td></tr> <tr><td>290</td><td>145</td><td>Request for oral hearing</td><td></td></tr> <tr><td>130</td><td>130</td><td>Petitions to the Commissioner</td><td></td></tr> <tr><td>180</td><td>180</td><td>Submission of Information Disclosure Statement</td><td>180.00</td></tr> <tr><td>770</td><td>385</td><td>Filing a submission after final rejection (37 CFR 1.129(a))</td><td></td></tr> <tr><td>770</td><td>385</td><td>For each additional invention to be examined (37 CFR 1.129(b))</td><td></td></tr> <tr><td>100</td><td>100</td><td>Certificate of Correction for applicant's error</td><td></td></tr> <tr><td>110</td><td>55</td><td>Submission of Terminal Disclaimer</td><td></td></tr> <tr><td colspan="2">Other fee (Specify)</td><td></td><td></td></tr> <tr><td colspan="2">Other fee (Specify)</td><td></td><td></td></tr> </tbody> </table>	Large Entity Fee (\$)	Small Entity Fee (\$)	Fee Description	Fee Paid	130	65	Surcharge - late filing fee or oath		50	25	Surcharge - late provisional filing fee or cover sheet		130	130	Non-English specification		2,520	2,520	Request for ex parte reexamination		110	55	Extension for reply within first month		420	210	Extension for reply within second month		950	475	Extension for reply within third month		1480	740	Extension for reply within fourth month		2010	1005	Extension for reply within fifth month		330	165	Notice of Appeal		330	165	Filing a brief in support of an appeal		290	145	Request for oral hearing		130	130	Petitions to the Commissioner		180	180	Submission of Information Disclosure Statement	180.00	770	385	Filing a submission after final rejection (37 CFR 1.129(a))		770	385	For each additional invention to be examined (37 CFR 1.129(b))		100	100	Certificate of Correction for applicant's error		110	55	Submission of Terminal Disclaimer		Other fee (Specify)				Other fee (Specify)															
Large Entity Fee (\$)	Small Entity Fee (\$)	Fee Description	Fee Paid																																																																																														
130	65	Surcharge - late filing fee or oath																																																																																															
50	25	Surcharge - late provisional filing fee or cover sheet																																																																																															
130	130	Non-English specification																																																																																															
2,520	2,520	Request for ex parte reexamination																																																																																															
110	55	Extension for reply within first month																																																																																															
420	210	Extension for reply within second month																																																																																															
950	475	Extension for reply within third month																																																																																															
1480	740	Extension for reply within fourth month																																																																																															
2010	1005	Extension for reply within fifth month																																																																																															
330	165	Notice of Appeal																																																																																															
330	165	Filing a brief in support of an appeal																																																																																															
290	145	Request for oral hearing																																																																																															
130	130	Petitions to the Commissioner																																																																																															
180	180	Submission of Information Disclosure Statement	180.00																																																																																														
770	385	Filing a submission after final rejection (37 CFR 1.129(a))																																																																																															
770	385	For each additional invention to be examined (37 CFR 1.129(b))																																																																																															
100	100	Certificate of Correction for applicant's error																																																																																															
110	55	Submission of Terminal Disclaimer																																																																																															
Other fee (Specify)																																																																																																	
Other fee (Specify)																																																																																																	
FEE CALCULATION 1. FILING FEE <table border="1" style="width: 100%; border-collapse: collapse; font-size: x-small;"> <thead> <tr> <th>Large Entity Fee (\$)</th> <th>Fee Description</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr><td>770</td><td>Utility filing fee</td><td></td></tr> <tr><td>340</td><td>Design filing fee</td><td></td></tr> <tr><td>160</td><td>Provisional filing fee</td><td></td></tr> </tbody> </table> <table border="1" style="width: 100%; border-collapse: collapse; font-size: x-small;"> <thead> <tr> <th></th> <th>Number Filed</th> <th>Number Extra</th> <th>Rate</th> <th>Amount</th> </tr> </thead> <tbody> <tr> <td>Total Claims</td> <td>- 20 =</td> <td></td> <td>x \$ 18.00 =</td> <td></td> </tr> <tr> <td>Independent Claims</td> <td>- 3 =</td> <td></td> <td>x \$ 86.00 =</td> <td></td> </tr> <tr> <td colspan="4"> <input type="checkbox"/> Multiple Dependent Claim(s), if any </td> <td>\$290.00 =</td> </tr> <tr> <td colspan="4" style="text-align: right;">TOTAL:</td> <td></td> </tr> <tr> <td colspan="4" style="text-align: right;">SMALL ENTITY DISCOUNT:</td> <td></td> </tr> <tr> <td colspan="4" style="text-align: right;">SUBTOTAL (1)</td> <td>(\$) 0.00</td> </tr> </tbody> </table> 2. AMENDMENT CLAIM FEES <table border="1" style="width: 100%; border-collapse: collapse; font-size: x-small;"> <thead> <tr> <th>Claims Remaining After Amend.</th> <th>Highest No. Previously Paid For</th> <th>Present Extra</th> <th>Rate</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr> <td>Total</td> <td>-</td> <td>=</td> <td>x \$ 18.00 =</td> <td></td> </tr> <tr> <td>Indep.</td> <td>-</td> <td>=</td> <td>x \$ 86.00 =</td> <td></td> </tr> <tr> <td colspan="4"> <input type="checkbox"/> First Presentation of Multiple Dep. Claim </td> <td>+ \$290.00 =</td> </tr> <tr> <td colspan="4" style="text-align: right;">TOTAL:</td> <td>(\$)</td> </tr> <tr> <td colspan="4" style="text-align: right;">SMALL ENTITY DISCOUNT:</td> <td>(\$)</td> </tr> <tr> <td colspan="4" style="text-align: right;">SUBTOTAL (2)</td> <td>(\$) 0.00</td> </tr> </tbody> </table>	Large Entity Fee (\$)	Fee Description	Fee Paid	770	Utility filing fee		340	Design filing fee		160	Provisional filing fee			Number Filed	Number Extra	Rate	Amount	Total Claims	- 20 =		x \$ 18.00 =		Independent Claims	- 3 =		x \$ 86.00 =		<input type="checkbox"/> Multiple Dependent Claim(s), if any				\$290.00 =	TOTAL:					SMALL ENTITY DISCOUNT:					SUBTOTAL (1)				(\$) 0.00	Claims Remaining After Amend.	Highest No. Previously Paid For	Present Extra	Rate	Fee Paid	Total	-	=	x \$ 18.00 =		Indep.	-	=	x \$ 86.00 =		<input type="checkbox"/> First Presentation of Multiple Dep. Claim				+ \$290.00 =	TOTAL:				(\$)	SMALL ENTITY DISCOUNT:				(\$)	SUBTOTAL (2)				(\$) 0.00	<table border="1" style="width: 100%; border-collapse: collapse; font-size: x-small;"> <tr> <td style="text-align: right;">SUBTOTAL (3)</td> <td>(\$) 180.00</td> </tr> <tr> <td colspan="2" style="height: 20px;"></td> </tr> <tr> <td style="text-align: right;">SUBTOTAL (1)</td> <td>0.00</td> </tr> <tr> <td style="text-align: right;">SUBTOTAL (2)</td> <td>0.00</td> </tr> <tr> <td style="text-align: right;">SUBTOTAL (3)</td> <td>180.00</td> </tr> <tr> <td colspan="2" style="height: 20px;"></td> </tr> <tr> <td style="text-align: right;">TOTAL</td> <td>(\$) 180.00</td> </tr> </table>	SUBTOTAL (3)	(\$) 180.00			SUBTOTAL (1)	0.00	SUBTOTAL (2)	0.00	SUBTOTAL (3)	180.00			TOTAL	(\$) 180.00
Large Entity Fee (\$)	Fee Description	Fee Paid																																																																																															
770	Utility filing fee																																																																																																
340	Design filing fee																																																																																																
160	Provisional filing fee																																																																																																
	Number Filed	Number Extra	Rate	Amount																																																																																													
Total Claims	- 20 =		x \$ 18.00 =																																																																																														
Independent Claims	- 3 =		x \$ 86.00 =																																																																																														
<input type="checkbox"/> Multiple Dependent Claim(s), if any				\$290.00 =																																																																																													
TOTAL:																																																																																																	
SMALL ENTITY DISCOUNT:																																																																																																	
SUBTOTAL (1)				(\$) 0.00																																																																																													
Claims Remaining After Amend.	Highest No. Previously Paid For	Present Extra	Rate	Fee Paid																																																																																													
Total	-	=	x \$ 18.00 =																																																																																														
Indep.	-	=	x \$ 86.00 =																																																																																														
<input type="checkbox"/> First Presentation of Multiple Dep. Claim				+ \$290.00 =																																																																																													
TOTAL:				(\$)																																																																																													
SMALL ENTITY DISCOUNT:				(\$)																																																																																													
SUBTOTAL (2)				(\$) 0.00																																																																																													
SUBTOTAL (3)	(\$) 180.00																																																																																																
SUBTOTAL (1)	0.00																																																																																																
SUBTOTAL (2)	0.00																																																																																																
SUBTOTAL (3)	180.00																																																																																																
TOTAL	(\$) 180.00																																																																																																

CORRESPONDENCE ADDRESS	SIGNATURE BLOCK
Direct all correspondence to: Patent Administrator Testa, Hurwitz & Thibault, LLP High Street Tower-125 High Street Boston, MA 02110 Tel. No.: (617) 248-7000 Fax No.: (617) 248-7100	Respectfully submitted,  Brian Fairchild, Ph.D. Attorney for the Applicants Testa, Hurwitz & Thibault, LLP High Street Tower-125 High Street Boston, MA 02110 Date: March 9, 2004 Reg. No.: 48,645 Tel. No.: (617) 248-7697 Fax No.: (617) 248-7100



PATENT
Attorney Docket No. MERCK-2056

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Hartmann *et al.*
SERIAL NO.: 09/708,506 GROUP NO.: 1647
FILING DATE: November 9, 2000 EXAMINER: DeBerry, Regina M.
TITLE: ERYTHROPOIETIN FORMS WITH IMPROVED PROPERTIES

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 9, 2004.


Malecia Allen

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith are:

1. Transmittal Form (1 page);
2. Fee Transmittal Form (1 page);
3. Supplemental Information Disclosure Statement (2 pages);
4. Form PTO-1449 (5 pages);
5. Copies of cited references A82-A96 and C191-C244;
6. A check in the amount of \$180.00; and
7. A return receipt postcard.



PATENT
Attorney Docket No. MERCK-2056

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Hartmann *et al.* CONF. NO.: 2626
SERIAL NO.: 09/708,506 GROUP NO.: 1647
FILING DATE: November 9, 2000 EXAMINER: DeBerry, Regina M.
TITLE: Erythropoietin Forms with Improved Properties

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☐ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☒ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☒ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or

- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.


Applicants believe no additional fee is due for consideration of this submission. Nevertheless, if such a fee is required, please debit account 20-0531.

Date: March 9, 2004
Reg. No. 48,645

Tel. No.: (617) 248-7697
Fax No.: (617) 248-7100

3034886-1

Respectfully submitted,



Brian Fairchild, Ph.D.
Attorney for Applicants
Testa, Hurwitz, & Thibault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110



FORM PTO - 1449				ATTORNEY DOCKET NO.: MERCK-2056			
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANTS: Hartmann et al.			
				SERIAL NO.: 09/708,506		CONF. NO.: 2626	
				FILING DATE: November 9, 2000		GROUP: 1647	
U.S. PATENT DOCUMENTS							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A82	4,703,008	10/27/87	Lin			
	A83	5,457,038	10/10/95	Trinchieri et al.			
	A84	5,547,933	8/20/96	Lin			
	A85	5,618,698	4/8/97	Lin			
	A86	5,756,349	5/26/98	Lin			
	A87	5,955,422	9/21/99	Lin			
	A88	6,231,536	5/15/01	Lentz			
	A89	6,284,536	9/4/01	Morrison et al.			
	A90	6,340,742	1/22/02	Burg et al.			
	A91	6,506,405	1/14/03	Desai et al.			
	A92	6,583,272	6/24/03	Bailon			
	A93	6,586,398	7/1/03	Kinstler et al.			
	A94	2002/0142374	10/3/02	Gallo et al.			
	A95	2003/0003529	1/2/03	Bayer			
	A96	2003/0012789	1/6/03	Blumberg et al.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)						
	C191	Angal et al., (1993), "A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody," <u>Molecular Immunology</u> , 30(1):105-108.					
	C192	Becker et al., (1996), "Long-lived and Transferable Tumor Immunity in Mice after Targeted Interleukin-2 Therapy," <u>J. Clin. Invest.</u> , 98(12):2801-2804.					
	C193	Becker et al., (1996), "T Cell-mediated Eradication of Murine Metastatic Melanoma Induced by Targeted Interleukin-2 Therapy," <u>J. Exp. Med.</u> , 183(50):2361-2366.					
	C194	Bitonti et al., (2002), "Transepithelial Absorption of an Erythropoietin-Fc Fusion Protein After Delivery to the Central Airways," <u>Respiratory Drug Delivery</u> , 8:309-312.					
	C195	Boissel et al., (1993), "Erythropoietin Structure-Function Relationships: Mutant Proteins that Test a Model of Tertiary Structure," <u>The Journal of Biological Chemistry</u> , 268(21):15983-15993.					
	C196	Briggs et al., (1974), "Hepatic Clearance of Intact and Desialylated Erythropoietin," <u>American Journal of Physiology</u> , 227(6):1385-1388.					
EXAMINER				DATE CONSIDERED			

FORM PTO - 1449

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056


APPLICANTS: Hartmann et al.

SERIAL NO.: 09/708,506 CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	C197	Chuang et al., (1994), "Alteration of Lymphocyte Microtubule Assembly, Cytotoxicity, and Activation by the Anticancer Drug Taxol," <u>Cancer Research</u> , 54:1286-1291.					
	C198	Darling et al., (2002), "Glycosylation of Erythropoietin Affects Receptor Binding Kinetics: Role of Electrostatic Interactions," <u>Biochemistry</u> , 41:14524-14531.					
	C199	Davis et al., (2003), "Immunocytokines: Amplification of Anti-cancer Immunity," <u>Cancer Immunol. Immunother.</u> , 52:297-308.					
	C200	Dolman et al., (1998), "Suppression of Human Prostate Carcinoma Metastases in Severe Combined Immunodeficient Mice by Interleukin 2 Immunocytokine Therapy," <u>Clin. Cancer Research</u> , 4(10):2551-2557.					
	C201	Duncan et al., (1988), "The Binding Site for C1q on IgG," <u>Nature</u> , 332:738-740.					
	C202	Egrie et al., (2001), "Development and Characterization of Novel Erythropoiesis Stimulating Protein (NESP)," <u>Nephrol. Dial. Transplant.</u> , 16(Supp 3):3-13.					
	C203	Elliott et al., (1997), "Mapping of the Active Site of Recombinant Human Erythropoietin," <u>Blood</u> , 89(2):493-502.					
	C204	Frost et al., (1997), "A Phase I/IB Trial of Murine Monoclonal Anti-GD2 Antibody 14.G2a Plus Interleukin-2 in Children with Refractory Neuroblastoma," <u>Cancer</u> , 80(2):317-333.					
	C205	Gan et al., (1999), "Specific Enzyme-linked Immunosorbent Assays for Quantitation of Antibody-cytokine Fusion Proteins," <u>Clinical and Diagnostic Laboratory Immunology</u> , 6(2):236-42.					
	C206	Gillies et al., (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-ganglioside GD2 Antibody," <u>Hybridoma</u> , 10(3):347-56.					
	C207	Gillies et al., (2002), "Bi-functional Cytokine Fusion Proteins for Gene Therapy and Antibody-targeted Treatment of Cancer," <u>Cancer Immunol. Immunother.</u> , 51(8):449-60.					
	C208	Gillies et al., (2002), "Improved Circulating Half-life and Efficacy of an Antibody-interleukin 2 Immunocytokine Based on Reduced Intracellular Proteolysis," <u>Clin. Cancer Research</u> , 8(1):210-216.					
	C209	Greene et al., (1975), "Neuronal Properties of Hybrid Neuroblastoma X Sympathetic Ganglion Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 72(12):4923-4927.					
	C210	Hank et al., (1996), "Activation of Human Effector Cells by a Tumor Reactive Recombinant Anti-ganglioside GD2 Interleukin-2 Fusion Protein (ch14.18-IL2)," <u>Clin. Cancer Research</u> , 2(12):1951-1959.					
	C211	Hank et al., (2003), "Determination of Peak Serum Levels and Immune Response to the Humanized Anti-ganglioside Antibody-interleukin-2 Immunocytokine," in <u>Methods in Molecular Medicine, Vol. 85: Novel Anticancer Drug Protocols</u> , Buolamwini et al., (eds.), pp. 123-131, Humana Press Inc., Totowana, NJ.					
	C212	Haraguchi, (1994), "Isolation of GD3 Synthase Gene by Expression Cloning of GM3 α -2,8-sialyltransferase cDNA using anti-GD2 Monoclonal Antibody," <u>Proc. Natl. Acad. Sci. USA</u> , 91(22):10455-10459.					
EXAMINER				DATE CONSIDERED			

 FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann et al. SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647			
U.S. PATENT DOCUMENTS							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	C213	Harris, (1995), "Processing of C-terminal Lysine and Arginine Residues of Proteins Isolated from Mammalian Cell Culture," <u>J. Chromatography A</u> , 705:129-134.					
	C214	Hezareh et al., (2001), "Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1," <u>J. Virology</u> , 75(24):12161-12168.					
	C215	Idusogie et al., (2000), "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," <u>J. Immunology</u> , 164(8):4178-4184.					
	C216	Imboden et al., (2001), "The Level of MHC Class I Expression on Murine Adenocarcinoma Can Change the Antitumor Effector Mechanism of Immunocytokine Therapy," <u>Cancer Research</u> , 61(4):1500-7.					
	C217	Kushner et al., (2001), "Phase II Trial of the Anti-GD2 Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma," <u>J. Clinical Oncology</u> , 19(22):4189-94.					
	C218	Lode et al., (1997), "Targeted Interleukin-2 Therapy for Spontaneous Neuroblastoma Metastases to Bone Marrow," <u>J. Natl. Cancer Inst.</u> , 89(21):1586-94.					
	C219	Lode et al., (2000), "What To Do With Targeted IL-2," <u>Drugs of Today</u> , 36(5):321-336.					
	C220	Lode et al., (2000), "Melanoma Immunotherapy by Targeted IL-2 Depends on CD4(+) T-cell Help Mediated by CD40/CD40L Interaction," <u>J. Clin. Invest.</u> , 105(11):1623-30.					
	C221	Metelitsa et al., (2002), "Antidisialoganglioside/granulocyte Macrophage-colony-stimulating Factor Fusion Protein Facilitates Neutrophil Antibody-dependent Cellular Cytotoxicity and Depends on FcγRII (CD32) and Mac-1 (CD11b/CD18) for Enhanced Effector Cell Adhesion and Azurophil Granule Exocytosis," <u>Blood</u> , 99(11):4166-73.					
	C222	Mueller et al., (1997), "Humanized Porcine VCAM-specific Monoclonal Antibodies with Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells," <u>Molecular Immunology</u> , 34(6):441-452.					
	C223	Mullins et al., (1997), "Taxol-mediated Changes in Fibrosarcoma-induced Immune Cell Function: Modulation of Antitumor Activities," <u>Cancer Immunol. Immunother.</u> , 45:20-28.					
	C224	Naramura et al., (1994), "Mechanisms of Cellular Cytotoxicity Mediated by a Recombinant Antibody-IL2 Fusion Protein Against Human Melanoma Cells," <u>Immunology Letters</u> , 39:91-99.					
	C225	Neal et al., (2003), "NXS2 Murine Neuroblastomas Express Increased Levels of MHC Class I Antigens upon Recurrence Following NK-dependent Immunotherapy," <u>Cancer Immunol. Immunother.</u> , 53:41-52.					
	C226	Ngo et al., (1994), "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," in <u>The Protein Folding Problem and Tertiary Structure Prediction</u> , Merz et al. (eds.), pp. 433-440 and 492-495, Birkhauser, Boston, MA.					
	C227	Niethammer et al., (2002) "An Oral DNA Vaccine Against Human Carcinoembryonic Antigen (CEA) Prevents Growth and Dissemination of Lewis Lung Carcinoma in CEA Transgenic Mice," <u>Vaccine</u> , 20:421-429.					
EXAMINER				DATE CONSIDERED			

FORM PTO - 1449

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056

APPLICANTS: Hartmann et al.

SERIAL NO.: 09/708,506 CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	C228	Niethammer et al., (2001) "Targeted Interleukin 2 Therapy Enhances Protective Immunity Induced by an Autologous Oral DNA Vaccine against Murine Melanoma," <u>Cancer Research</u> , 61(16):6178-84.					
	C229	Pancook et al., (1996), "Eradication of Established Hepatic Human Neuroblastoma Metastases in Mice with Severe Combined Immunodeficiency by Antibody-targeted Interleukin-2," <u>Cancer Immunol. Immunother.</u> , 42(2):88-92.					
	C230	Park et al., (2000), "Efficiency of promoter and cell line in high-level expression of erythropoietin," <u>Biotechnol. Appl. Biochem.</u> , 32:167-172.					
	C231	Reisfeld et al., (1996), "Antibody-interleukin 2 Fusion Proteins: A New Approach to Cancer Therapy," <u>J. Clin. Lab. Anal.</u> , 10:160-166.					
	C232	Reisfeld et al., (1996), "Involvement of B Lymphocytes in the Growth Inhibition of Human Pulmonary Melanoma Metastases in Athymic <i>nu/nu</i> Mice by an Antibody-lymphotoxin Fusion Protein," <u>Cancer Research</u> , 56(8):1707-1712.					
	C233	Ruehlmann et al., (2001), "MIG (CIXCL9) Chemokine Gene Therapy Combines with Antibody-cytokine Fusion Protein to Suppress Growth and Dissemination of Murine Colon Carcinoma," <u>Cancer Research</u> , 61(23):8498-503.					
	C234	Sabzevari et al., (1994), "A Recombinant Antibody-interleukin 2 Fusion Protein Suppresses Growth of Hepatic Human Severe Combined Immunodeficiency Mice," <u>Proc. Natl. Acad. Sci. USA</u> , 91(20):9626-30.					
	C235	Shinkawa et al., (2003), "The Absence of Fucose But Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity," <u>J. Biol. Chem.</u> , 278:3466-3473.					
	C236	Strom et al., (1996), "Therapeutic Approach to Organ Transplantation," Chapter 36, pp. 451-456, in <u>Therapeutic Immunology</u> , Austen et al., (eds.), Blackwell Science.					
	C237	Thommesen et al., (2000), "Lysine 322 in the Human IgG3 CH2 Domain is Crucial for Antibody Dependent Complement Activation," <u>Mol. Immunol.</u> , 37(16):995-1004.					
	C238	Wells, (1990), "Additivity of Mutational Effect in Proteins," <u>Biochemistry</u> , 29(37):8509-8517.					
	C239	Xiang et al., (1998), "Induction of Persistent Tumor-protective Immunity in Mice Cured of Established Colon Carcinoma Metastases," <u>Cancer Research</u> , 58(17):3918-3925.					
	C240	Xiang et al., (1999) "T Cell Memory against Colon Carcinoma is Long-lived in the Absence of Antigen," <u>J. Immunology</u> , 163(7):3676-83.					
	C241	Xiang et al., (2001), "A Dual Function DNA Vaccine Encoding Carcinoembryonic Antigen and CD40 Ligand Trimer Induces T Cell-mediated Protective Immunity Against Colon Cancer in Carcinoembryonic Antigen-Transgenic Mice," <u>J. Immunology</u> , 167(8):4560-5.					
	C242	Xiang et al., (2001), "Protective Immunity Against Human Carcinoembryonic Antigen (CEA) Induced by an Oral DNA Vaccine in CEA-transgenic Mice," <u>Clinical Cancer Research</u> , 7(3 Supp):S856-S864.					
EXAMINER				DATE CONSIDERED			



FORM PTO - 1449				ATTORNEY DOCKET NO.: MERCK-2056			
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANTS: Hartmann et al.			
				SERIAL NO.: 09/708,506		CONF. NO.: 2626	
				FILING DATE: November 9, 2000		GROUP: 1647	
U.S. PATENT DOCUMENTS							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	C243	Yu et al., (1998), "Phase I Trial of a Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 in Patients with Refractory Neuroblastoma and Osteosarcoma," <u>J. Clinical Oncology</u> , 16(6):2169-80.					
	C244	Zagozdzon et al., (1999), "Potentiation of Antitumor Effects of IL-12 in Combination with Paclitaxel in Murine Melanoma Model <i>In Vivo</i> ," <u>International Journal of Molecular Medicine</u> , 4:645-648.					
EXAMINER				DATE CONSIDERED			

3034826_1